SEC Filing Summary: Frequency Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on March 29, 2021. The report announces financial results and operational updates for the quarter and full year ended December 31, 2020. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing does not provide specific data to compare current period performance against prior periods. It serves as a notification that results for the period ended December 31, 2020, have been announced.
Guidance, Outlook, and Risks
The company provided operational updates alongside the financial results, though specific guidance or risk factors are not detailed in the filing text. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability and incorporation by reference.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the full text of the March 29, 2021 press release (Exhibit 99.1).
- Confirm the operational updates regarding clinical trials or product development mentioned in the press release.
- Note that the registrant is Frequency Therapeutics, Inc., trading under the symbol FREQ on the Nasdaq Global Select Market.
- Review the "furnished" status of the financial data to understand its legal standing regarding liability.